Microcapsule Enzyme Therapy for PKU Blood Phenylalanine Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for phenylketonuria (PKU), such as low-L-phenylalanine-content diets and gene therapy, face compliance issues and nutritional deficiencies, and gene therapy methods are rejected due to immune responses, necessitating an alternative therapeutic approach.
Innovation Solution
A pharmaceutical composition comprising microcapsules with a semi-permeable ethyl cellulose membrane containing phenylalanine ammonia lyase and either hemoglobin or fatty acid-free albumin, allowing L-phenylalanine to pass through while preventing larger molecules, which are administered orally to reduce blood L-phenylalanine levels and alleviate PKU symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If low-L-Phe-content synthetic diet is used to treat PKU, then blood L-Phe levels are reduced, but nutritional deficiencies and growth retardation occur
Solution Approach 1:
The patent introduces microcapsules containing phenylalanine ammonia-lyase enzyme as an intermediary therapeutic agent. These microcapsules selectively convert excess L-Phe to trans-cinnamic acid in the gastrointestinal tract, thereby reducing blood L-Phe levels without requiring restriction of overall dietary protein intake. This mediator approach allows patients to maintain normal nutrition while achieving therapeutic L-Phe control.
Solution Approach 2:
The invention changes the chemical parameter of L-Phe by introducing an enzymatic conversion reaction. The phenylalanine ammonia-lyase enzyme catalyzes the conversion of L-Phe to trans-cinnamic acid, fundamentally altering the metabolic pathway and allowing L-Phe reduction through chemical transformation rather than dietary restriction.
2Reliability
If low-L-Phe-content synthetic diet is continued for lifetime, then neurotoxicity is prevented, but compliance deteriorates in adolescents and adults
Solution Approach 1:
The therapeutic approach is segmented into discrete microcapsule units that can be easily administered. Each microcapsule contains the therapeutic enzyme and can be taken as a simple supplement alongside normal diet, rather than requiring continuous dietary monitoring and restriction. This segmentation makes the therapy manageable and compliant, especially for adolescents and adults.
Solution Approach 2:
The microcapsules perform self-service therapy by containing the phenylalanine ammonia-lyase enzyme that automatically converts excess L-Phe to trans-cinnamic acid in the gastrointestinal tract. The therapeutic action occurs autonomously after ingestion, without requiring patient adherence to complex dietary restrictions, thereby ensuring consistent neuroprotection regardless of patient compliance with dietary guidelines.
3Reliability
If gene therapy is used to correct PAH activity, then enzyme function is improved, but immune response leads to therapy rejection
Solution Approach 1:
Instead of directly modifying genes (which triggers immune response), the patent uses phenylalanine ammonia-lyase enzyme microcapsules as an intermediary therapeutic agent. This enzyme provides an alternative metabolic pathway that bypasses the defective PAH enzyme, achieving therapeutic effect without exposing the immune system to foreign genetic material or viral vectors.
Solution Approach 2:
The microcapsules are designed as temporary, disposable therapeutic units rather than permanent genetic modifications. Each microcapsule provides short-term enzymatic activity that converts L-Phe to trans-cinnamic acid, and is then eliminated naturally. This approach avoids the long-term immune recognition and rejection issues associated with permanent gene therapy interventions.
4Quantity of substance
If microcapsule membrane is made permeable to L-Phe, then substrate access is improved, but larger molecules may leak
Solution Approach 1:
The microcapsule membrane exhibits local quality characteristics with different permeability properties for different molecules. It is specifically designed to be permeable to small L-Phe molecules while retaining larger enzyme molecules inside. This selective local permeability allows substrate access while preventing enzyme leakage, resolving the contradiction between substrate access and molecular retention.
Solution Approach 2:
The membrane is constructed as a porous material with specific pore size characteristics that allow passage of small L-Phe molecules while blocking larger enzyme molecules. The porous structure provides size-based selectivity, enabling L-Phe permeability while maintaining enzyme retention within the microcapsule interior.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The microcapsule composition effectively converts L-phenylalanine to non-toxic trans-cinnamic acid, reducing blood L-phenylalanine levels and treating PKU symptoms without the drawbacks of existing treatments, including improved nutritional balance and reduced immune rejection.
Implementation Method 1
L-phenylalanine flows freely across the membrane, and wherein a polypeptide with a molecular weight greater than about 20 kD cannot significantly cross the membrane
Implementation Method 2
phenylalanine ammonia lyase catalyzes the conversion of L-phenylalanine to trans-cinnamic acid and ammonia
Data Source
AI summary
The present invention provides compositions for the treatment of phenylketonuria in mammals, as well as methods of preparing said compositions. The present invention also provides methods of treating phenylketonuria using the compositions of the invention.